CEO Koenraad Wiedhaup recently had the opportunity to share the mission of Leyden Labs with Brad Loncar of Biotech TV during a stop in Leiden on the team's 2024 European Biotech Tour. They discussed the limitations of vaccination to fully protect against respiratory viruses, as well as the rationale for the approach of Leyden Labs to combine mucosal delivery with broad protection through the intranasal antibody formulations in the pipeline.

Click here to read the article on the Biotech TV website or watch the interview video at this Vimeo link.